Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 948-066-8 | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Basic toxicokinetics
Administrative data
- Endpoint:
- basic toxicokinetics, other
- Type of information:
- other: Expert statement
- Adequacy of study:
- weight of evidence
- Study period:
- 2019
- Reliability:
- other: not relevant for expert statement
Data source
Materials and methods
- Objective of study:
- toxicokinetics
Test guideline
- Qualifier:
- no guideline required
- Principles of method if other than guideline:
- Expert statement
- GLP compliance:
- no
Test material
- Reference substance name:
- Ethanol, 2-(2-butoxyethoxy)-, reaction products with phosphorus oxide (P2O5), compds. with N,N-dimethylcyclohexanamine
- EC Number:
- 948-066-8
- Molecular formula:
- C16H36NO6P C24H52NO8P C24H53NO11P2 C32H68NO10P C8H17N H3O4P
- IUPAC Name:
- Ethanol, 2-(2-butoxyethoxy)-, reaction products with phosphorus oxide (P2O5), compds. with N,N-dimethylcyclohexanamine
- Test material form:
- liquid: viscous
Constituent 1
Results and discussion
Main ADME results
- Type:
- absorption
- Results:
- 100% (oral), 10% (inhalation), 15% (dermal)
Toxicokinetic / pharmacokinetic studies
- Details on absorption:
- Oral :
After oral administration, a compound needs to be dissolved before it can be taken up from
the gastrointestinal tract1. Since the water solubility of Ethanol, 2-(2-butoxyethoxy)-, reaction products with phosphorus oxide (P2O5), compds. with N,N-dimethylcyclohexanamine is high
(> 1000 g/L), the substance is expected to be totally dissolved in gastrointestinal fluids,therefore the availability for uptake is expected to be high. Based on its moderate molecular weight (242-386), uptake via passive diffusion might occur, but might be too big for passage through aqueous pores or carriage across membranes with the bulk passage of water. Tetradecafluorohexane has a relatively low partition coefficient (log Pow < 4.5), which is considered favourable for passive diffusion, and thus high absorption. The substance have ionisable groups that could influence its absorption. However, as the substance is acid, thus gastric acid is not expected to modify the ionisation form nor the absorption.
For risk assessment purposes, oral absorption of Ethanol, 2-(2-butoxyethoxy)-, reaction products with phosphorus oxide (P2O5), compds. with N,N-dimethylcyclohexanamine is set at 100%, based on its high water solubility, moderate molecular weight and low log Pow. The oral toxicity data do not provide reasons to deviate from the proposed oral absorption factor2.
Respiratory :
Ethanol, 2-(2-butoxyethoxy)-, reaction products with phosphorus oxide (P2O5), compds. with N,N-dimethylcyclohexanamine has high water solubility, so its dissolution in mucus lining in the respiratory tract may be high. Moreover, Ethanol, 2-(2-butoxyethoxy)-, reaction products with phosphorus oxide (P2O5), compds. with N,N-dimethylcyclohexanamine has a low partition coefficient (log Pow < 4.5), which is considered favourable for passive diffusion through biological membranes. However, Ethanol, 2-(2-butoxyethoxy)-, reaction products with phosphorus oxide (P2O5), compds. with N,N-dimethylcyclohexanamine has a very low vapour pressure (2.07 x 10-4 Pa at 20 °C ), which indicates that Ethanol, 2-(2-butoxyethoxy)-, reaction products with phosphorus oxide (P2O5), compds. with N,N-dimethylcyclohexanamine is not volatile and exposure by inhalation is not expected. A very limited amount of vapours, not lipophilic (log Pow < 4) does not have the ability to reach the deep lung, thus absorption through gas exchange may only marginally occur.
Ethanol, 2-(2-butoxyethoxy)-, reaction products with phosphorus oxide (P2O5), compds. with N,N-dimethylcyclohexanamine is a liquid, which indicates that exposure via areosols is also possible.
Aerosols can reach the tracheobronquial region of the respiratory tract. Taking in consideration all these factors together, it is concluded that for risk assessment purposes, the inhalation absorption should be set at 10%2.
Dermal :
Ethanol, 2-(2-butoxyethoxy)-, reaction products with phosphorus oxide (P2O5), compds. with N,N-dimethylcyclohexanamine is a liquid with high water solubility, it will dissolve
into the surface moisture of the skin to allow uptake. The relatively low logPow (<4) indicates the crossing of epidermal barriers will occur. According to the criteria given in the REACH Guidance2, a default value of 100% dermal absorption has been established if the molecular weight is lower than 500 and log P between -1 and 4. The physical/chemical properties of Ethanol, 2-(2-butoxyethoxy)-, reaction products with phosphorus oxide (P2O5), compds. with N,N-dimethylcyclohexanamine fully meet the criteria for full dermal absorption (MW 242-386; log Pow <4.5).
Ethanol, 2-(2-butoxyethoxy)-, reaction products with phosphorus oxide (P2O5), compds. with N,N-dimethylcyclohexanamine skin corrosive, so enhanced uptake related to local effects is expected, but skin contact is not expected and may be very limited in time. Acute dermal toxicity study did not show mortality at 2000 mg/kg. As mortality was observed form 300 mg/kg by oral route, it can be concluded that dermal absorption is lower than 15 %. For risk assessment purpose, as a conservative hypothesis, dermal absorption is set at 15%.
Applicant's summary and conclusion
- Conclusions:
- A toxicokinetic assessment was performed based on the available data of the substance.
Based on the physical/chemical properties of the substance, absorption factors for this
substance arederived to be 100% (oral), 10% (inhalation) and 15% (dermal) for risk
assessment purposes. The bioaccumulation potential is expected to be low. - Executive summary:
A substance can enter the body via de gastrointestinal tract, the lungs, and the skin1. Since
different parameters are relevant for absorption via the different routes of exposure, the
uptake via these three routes will be addressed individually.
Oral :
After oral administration, a compound needs to be dissolved before it can be taken up from
the gastrointestinal tract1. Since the water solubility of Ethanol, 2-(2-butoxyethoxy)-, reaction products with phosphorus oxide (P2O5), compds. with N,N-dimethylcyclohexanamine is high
(> 1000 g/L), the substance is expected to be totally dissolved in gastrointestinal fluids,therefore the availability for uptake is expected to be high. Based on its moderate molecular weight (242-386), uptake via passive diffusion might occur, but might be too big for passage through aqueous pores or carriage across membranes with the bulk passage of water. Tetradecafluorohexane has a relatively low partition coefficient (log Pow < 4.5), which is considered favourable for passive diffusion, and thus high absorption. The substance have ionisable groups that could influence its absorption. However, as the substance is acid, thus gastric acid is not expected to modify the ionisation form nor the absorption.
For risk assessment purposes, oral absorption of Ethanol, 2-(2-butoxyethoxy)-, reaction products with phosphorus oxide (P2O5), compds. with N,N-dimethylcyclohexanamine is set at 100%, based on its high water solubility, moderate molecular weight and low log Pow. The oral toxicity data do not provide reasons to deviate from the proposed oral absorption factor2.
Respiratory :
Ethanol, 2-(2-butoxyethoxy)-, reaction products with phosphorus oxide (P2O5), compds. with N,N-dimethylcyclohexanamine has high water solubility, so its dissolution in mucus lining in the respiratory tract may be high. Moreover, Ethanol, 2-(2-butoxyethoxy)-, reaction products with phosphorus oxide (P2O5), compds. with N,N-dimethylcyclohexanamine has a low partition coefficient (log Pow < 4.5), which is considered favourable for passive diffusion through biological membranes. However, Ethanol, 2-(2-butoxyethoxy)-, reaction products with phosphorus oxide (P2O5), compds. with N,N-dimethylcyclohexanamine has a very low vapour pressure (2.07 x 10-4 Pa at 20 °C ), which indicates that Ethanol, 2-(2-butoxyethoxy)-, reaction products with phosphorus oxide (P2O5), compds. with N,N-dimethylcyclohexanamine is not volatile and exposure by inhalation is not expected. A very limited amount of vapours, not lipophilic (log Pow < 4) does not have the ability to reach the deep lung, thus absorption through gas exchange may only marginally occur.
Ethanol, 2-(2-butoxyethoxy)-, reaction products with phosphorus oxide (P2O5), compds. with N,N-dimethylcyclohexanamine is a liquid, which indicates that exposure via areosols is also possible.
Aerosols can reach the tracheobronquial region of the respiratory tract. Taking in consideration all these factors together, it is concluded that for risk assessment purposes, the inhalation absorption should be set at 10%2.
Dermal :
Ethanol, 2-(2-butoxyethoxy)-, reaction products with phosphorus oxide (P2O5), compds. with N,N-dimethylcyclohexanamine is a liquid with high water solubility, it will dissolve
into the surface moisture of the skin to allow uptake. The relatively low logPow (<4) indicates the crossing of epidermal barriers will occur. According to the criteria given in the REACH Guidance2, a default value of 100% dermal absorption has been established if the molecular weight is lower than 500 and log P between -1 and 4. The physical/chemical properties of Ethanol, 2-(2-butoxyethoxy)-, reaction products with phosphorus oxide (P2O5), compds. with N,N-dimethylcyclohexanamine fully meet the criteria for full dermal absorption (MW 242-386; log Pow <4.5).
Ethanol, 2-(2-butoxyethoxy)-, reaction products with phosphorus oxide (P2O5), compds. with N,N-dimethylcyclohexanamine skin corrosive, so enhanced uptake related to local effects is expected, but skin contact is not expected and may be very limited in time. Acute dermal toxicity study did not show mortality at 2000 mg/kg. As mortality was observed form 300 mg/kg by oral route, it can be concluded that dermal absorption is lower than 15 %. For risk assessment purpose, as a conservative hypothesis, dermal absorption is set at 15%.
Once absorbed, distribution of the substance throughout the body is expected to be high
based on its high water solubility, relatively low log Pow and moderate molecular
weight. Orally absorbed Ethanol, 2-(2-butoxyethoxy)-, reaction products with phosphorus oxide (P2O5), compds. with N,N-dimethylcyclohexanamine may be metabolized in the gastrointestinal tract or the liver and excreted through bile and urine. Based on its relatively low partition coefficient (log Pow < 4.5), Ethanol, 2-(2-butoxyethoxy)-, reaction products with phosphorus oxide (P2O5), compds. with N,N-dimethylcyclohexanamine is not expected to accumulate in adipose tissue (intracellular concentration may not be higher than the extracellular concentration). The overall bioaccumulation potential of Ethanol, 2-(2-butoxyethoxy)-, reaction products with phosphorus oxide (P2O5), compds. with N,N-dimethylcyclohexanamine is expected to be low.
CONCLUSION
A toxicokinetic assessment was performed based on the available data of the substance.
Based on the physical/chemical properties of the substance, absorption factors for this
substance arederived to be 100% (oral), 10% (inhalation) and 15% (dermal) for risk
assessment purposes. The bioaccumulation potential is expected to be low.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.